EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Treatment of non–small cell lung cancer with RET rearrangements

Hui Jing Hoe iD, Benjamin J Solomon

Cancer · 2025

DOI: 10.1002/cncr.35779 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Hui Jing Hoe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-ret, Lung Neoplasms, Gene Rearrangement. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of the RET oncogene by mutations or gene fusions drives various malignancies, including 1%–2% of all non–small cell lung cancers (NSCLCs) that harbor RET gene fusions. Initial attempts to target RET fusion–positive NSCLC with poorly selective multikinase RET inhibitors were associated with significant toxicities and limited efficacy. Two highly potent and selective RET small‐molecule inhibitors, selpercatinib and pralsetinib, were granted accelerated approval for advanced RET fusion–positive NSCLC by the US Food and Drug Administration, and have been shown to be highly effective both in treatment‐naive and previously treated patients with NSCLC. Selpercatinib has shown superiority over chemotherapy in a phase 3 study (LIBRETTO‐431) in previously untreated patients with RET fusion–positive NSCLC, which established its place as the standard of care in this patient population. This review discusses the biology and clinical characteristics of RET ‐rearranged NSCLC and summarizes the evolution of treatment strategies, current understanding of mechanisms of resistance, and development of new‐generation agents to overcome resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins c-retLung NeoplasmsGene RearrangementProtein Kinase InhibitorsHumansDrug Resistance, NeoplasmPyrazolesOncogene Proteins, FusionPyridinesPyrimidines

Stichwörter der Autor:innen

RETRET NSCLCRET fusionRET rearrangementslung cancernon–small cell lung cancer (NSCLC)pralsetinibselpercatinib

Substanzen

Proto-Oncogene Proteins c-retRET protein, humanProtein Kinase InhibitorsselpercatinibpralsetinibPyrazolesOncogene Proteins, FusionPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Hui Jing Hoe

Zitieren

APA

Hoe, H. J., & Solomon, B. J. (2025). Treatment of non–small cell lung cancer with RET rearrangements. Cancer. https://doi.org/10.1002/cncr.35779

Vancouver

Hoe HJ, Solomon BJ. Treatment of non–small cell lung cancer with RET rearrangements. Cancer. 2025. doi:10.1002/cncr.35779

BibTeX
@article{Hoe2025,
  author = {Hoe, Hui Jing and Solomon, Benjamin J},
  title = {Treatment of non–small cell lung cancer with RET rearrangements},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35779}
}
Kostenlos starten →